{"protocolSection":{"identificationModule":{"nctId":"NCT01949090","orgStudyIdInfo":{"id":"200613"},"organization":{"fullName":"GlaxoSmithKline","class":"INDUSTRY"},"briefTitle":"Immunogenicity and Safety Study of Different Formulations of GlaxoSmithKline (GSK) Biologicals H7N1 Influenza Vaccine Administered to Adults 65 Years of Age and Older","officialTitle":"An Observer-blind Study to Evaluate the Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine(s) GSK2789869A Administered in Adults 65 Years of Age and Older"},"statusModule":{"statusVerifiedDate":"2017-11","overallStatus":"COMPLETED","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2013-09-25","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2013-12-04","type":"ACTUAL"},"completionDateStruct":{"date":"2014-10-23","type":"ACTUAL"},"studyFirstSubmitDate":"2013-09-19","studyFirstSubmitQcDate":"2013-09-19","studyFirstPostDateStruct":{"date":"2013-09-24","type":"ESTIMATED"},"resultsFirstSubmitDate":"2017-08-25","resultsFirstSubmitQcDate":"2017-11-13","resultsFirstPostDateStruct":{"date":"2017-11-17","type":"ACTUAL"},"dispFirstSubmitDate":"2014-05-29","dispFirstSubmitQcDate":"2014-05-29","dispFirstPostDateStruct":{"date":"2014-06-02","type":"ESTIMATED"},"lastUpdateSubmitDate":"2017-11-13","lastUpdatePostDateStruct":{"date":"2017-11-17","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"GlaxoSmithKline","class":"INDUSTRY"}},"descriptionModule":{"briefSummary":"The purpose of this placebo controlled study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals H7N1 influenza vaccine in subjects 65 years of age and older. The study will evaluate safety related events and antibody immune responses to different formulations of study vaccine."},"conditionsModule":{"conditions":["Influenza"],"keywords":["H7N1","AS03 adjuvant","Safety","Immunogenicity","Influenza","Adults","Elderly adults"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"PREVENTION","maskingInfo":{"masking":"QUADRUPLE","whoMasked":["PARTICIPANT","CARE_PROVIDER","INVESTIGATOR","OUTCOMES_ASSESSOR"]}},"enrollmentInfo":{"count":363,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"GSK2789869A F1 Group","type":"EXPERIMENTAL","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","interventionNames":["Biological: Investigational H7N1 vaccine GSK2789869A"]},{"label":"GSK2789869A F2 Group","type":"EXPERIMENTAL","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","interventionNames":["Biological: Investigational H7N1 vaccine GSK2789869A"]},{"label":"GSK2789869A F3 Group","type":"EXPERIMENTAL","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","interventionNames":["Biological: Investigational H7N1 vaccine GSK2789869A"]},{"label":"GSK2789869A F4 Group","type":"EXPERIMENTAL","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","interventionNames":["Biological: Investigational H7N1 vaccine GSK2789869A"]},{"label":"Placebo Group","type":"PLACEBO_COMPARATOR","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","interventionNames":["Biological: Placebo"]}],"interventions":[{"type":"BIOLOGICAL","name":"Investigational H7N1 vaccine GSK2789869A","description":"Two doses of GSK2789869A H7N1 vaccine administered intramuscularly to the deltoid region at Day 0 and Day 21.","armGroupLabels":["GSK2789869A F1 Group","GSK2789869A F2 Group","GSK2789869A F3 Group","GSK2789869A F4 Group"]},{"type":"BIOLOGICAL","name":"Placebo","description":"Two doses of placebo administered intramuscularly to the deltoid region at Day 0 and Day 21.","armGroupLabels":["Placebo Group"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against the Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain","description":"Seroconversion was defined as: For initially seronegative subjects \\[antibody titer below (\\<) 10 post-vaccination\\], antibody titer greater than or equal to (≥) 40 after vaccination; For initially seropositive subjects (antibody titer ≥ 10 prior to vaccination), antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was A/mallard/Netherlands/12/2000 NIBRG-63 (H7N1) (Flu A/mallard/NL/12/2000 H7N1).","timeFrame":"At Day 42"},{"measure":"Number of Subjects Who Were Seroprotected for HI Antibodies Against the Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain","description":"A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40, that usually is accepted as indicating protection.","timeFrame":"At Day 42"},{"measure":"Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain","description":"GMFR, also known as seroconversion factor (SCR) or mean geometric increase (MGI), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer for the vaccine virus.","timeFrame":"At Day 42"},{"measure":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest; prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","timeFrame":"During the 7-day (Days 0-6) post-vaccination period following each dose and across doses"},{"measure":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, joint pain at other location, muscle aches, shivering, sweating and fever \\[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = general symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever = temperature \\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","timeFrame":"During the 7-day (Days 0-6) post-vaccination period following each dose and across doses"},{"measure":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","timeFrame":"At Day 0"},{"measure":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","timeFrame":"At Day 7"},{"measure":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","timeFrame":"At Day 21"},{"measure":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","timeFrame":"At Day 28"},{"measure":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","timeFrame":"At Day 42"},{"measure":"Number of Subjects With Any Medically-attended Adverse Events (MAEs)","description":"MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.","timeFrame":"From Day 0 up to Day 42"},{"measure":"Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)","description":"Any pIMD was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.","timeFrame":"From Day 0 up to Day 42"},{"measure":"Number of Subjects With Any Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","timeFrame":"From Day 0 up to Day 42"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"From Day 0 up to Day 42"}],"secondaryOutcomes":[{"measure":"Number of Subjects With HI Antibody Concentrations Above the Cut-off Value for Vaccine-homologous (H7N1)","description":"Seropositivity cut-off values assessed were equal to or above (≥) 1:10 in the sera of subjects seronegative before vaccination. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","timeFrame":"At Days 0, 21, 42 and Months 6 and 12"},{"measure":"Titers for Antibodies Against Flu A/Mallard/NL/12/2000 Strain of Influenza Disease Vaccine-homologous (H7N1)","description":"Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","timeFrame":"At Days 0, 21, 42 and Months 6 and 12"},{"measure":"Number of Seroprotected (SPR) Subjects Against HI Antibodies for Vaccine-homologous (H7N1)","description":"Seroprotection (SPR) was defined as the proportion of subjects with H7N1 reciprocal HI titers equal to or above (≥) 1:40 against the tested vaccine virus. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","timeFrame":"At Days 0, 21 and 42 and at Months 6 and 12"},{"measure":"Number of Seroconverted (SCR) Subjects for HI Antibodies for Vaccine-homologous (H7N1)","description":"SCR was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer \\< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","timeFrame":"At Days 21 and 42 and at Months 6 and 12"},{"measure":"Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/Mallard/NL/12/2000 Strain of Influenza Disease Vaccine-homologous (H7N1)","description":"GMFR, also known as seroconversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","timeFrame":"At Days 21 and 42 and at Months 6 and 12"},{"measure":"Number of Subjects With HI Antibody Concentrations Above the Cut-off Value for Vaccine-heterologous (H7N9)","description":"Seropositivity cut-off values assessed were equal to or above (≥) 1:10 in the sera of subjects seronegative before vaccination. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","timeFrame":"At Days 0, 21 and 42 and at Months 6 and 12"},{"measure":"Titers for Antibodies Against Flu A/Shanghai/2/2013 Strain of Influenza Disease Vaccine-heterologous (H7N9)","description":"Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","timeFrame":"At Days 0, 21 and 42 and at Months 6 and 12"},{"measure":"Number of Seroprotected (SPR) Subjects Against HI Antibodies for Vaccine-heterologous (H7N9)","description":"Seroprotection (SPR) was defined as the proportion of subjects with H7N9 reciprocal HI titers equal to or above (≥) 1:40 against the tested vaccine virus. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","timeFrame":"At Days 0, 21 and 42 and at Months 6 and 12"},{"measure":"Number of Seroconverted (SCR) Subjects for HI Antibodies for Vaccine-heterologous (H7N9)","description":"SCR was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer \\< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","timeFrame":"At Days 21 and 42 and at Months 6 and 12"},{"measure":"Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/Shanghai/2/2013 Strain of Influenza Disease Vaccine-heterologous (H7N9)","description":"GMFR, also known as seroconversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","timeFrame":"At Days 21 and 42 and at Months 6 and 12"},{"measure":"Number of Subjects With HI Neutralizing Antibody Concentrations Above the Cut-off Value for Vaccine-homologous (H7N1)","description":"Seropositivity cut-off values assessed were equal to or above (≥) 1:28 in the sera of subjects seronegative before vaccination. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","timeFrame":"At Days 0, 21 and 42 and Month 6"},{"measure":"Titers for Serum Neutralizing Antibodies Against Flu A/Mallard/NL/12/2000 Strain of Influenza Disease Vaccine-homologous (H7N1)","description":"Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/mallard/NL/12/2000. The reference seropositivity cut-off value was ≥ 1:28.","timeFrame":"At Days 0, 21 and 42 and at Month 6"},{"measure":"Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain","description":"Vaccine response was defined as: For initially seronegative subjects antibody titer ≥ 1:56 at post-vaccination\\]; For initially seropositive subjects antibody titer at post-vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","timeFrame":"At Days 21 and 42 and at Month 6"},{"measure":"Number of Subjects With HI Neutralizing Antibody Concentrations Above the Cut-off Value for Vaccine-heterologous (H7N9)","description":"Seropositivity cut-off values assessed were equal to or above (≥) 1:28 in the sera of subjects seronegative before vaccination. The flu strain assessed was Flu A/Anhui/1/2013 (H7N9).","timeFrame":"At Days 0, 21 and 42 and at Month 6"},{"measure":"Titers for Antibodies Against Flu A/Anhui/1/2013 Strain of Influenza Disease Vaccine-homologous (H7N9)","description":"Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/Anhui/1/2013. The reference seropositivity cut-off value was ≥ 1:28.","timeFrame":"At Days 0, 21 and 42 and at Month 6"},{"measure":"Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the Flu A/Anhui/1/2013 (H7N9) Virus Strain","description":"Vaccine response was defined as: For initially seronegative subjects antibody titer ≥ 1:56 at post-vaccination\\]; For initially seropositive subjects antibody titer at post-vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was Flu A/Anhui/1/2013 (H7N9).","timeFrame":"At Days 21 and 42 and at Month 6"},{"measure":"Number of Subjects With Any Medically-attended Adverse Events (MAEs)","description":"MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. Analysis of intensity and relationship to vaccination of MAEs was not performed.","timeFrame":"From Day 42 up to Month 12"},{"measure":"Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)","description":"An pIMD was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.","timeFrame":"From Day 42 up to Month 12"},{"measure":"Number of Subjects With Any Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","timeFrame":"During the 21-day (From Day 0 to Day 20) post-vaccination period after each dose"},{"measure":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","timeFrame":"During the entire study period (From Day 0 up to Month 12)"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Male or female adults who are 65 years of age and older at the time of first study vaccination.\n* Written informed consent obtained from the subject.\n* Subjects who the investigator believes can and will comply with the requirements of the protocol.\n* Stable health status, as established by medical history and physical exam, and defined by absence of a health event satisfying the definition of a serious adverse event, or a change in an ongoing drug therapy due to therapeutic failure or symptoms of drug toxicity, within 1 month prior to enrollment.\n* Access to a consistent means of telephone contact, which may be either in the home or at the workplace, land line or mobile, but NOT a pay phone or other multiple-user device.\n\nExclusion Criteria:\n\n* Presence or evidence of neurological or psychiatric diagnoses which, although stable, are deemed by the investigator to render the potential subject unable/unlikely to provide accurate safety reports.\n* Presence or evidence of substance abuse.\n* Diagnosed with cancer, or treatment for cancer within three years.\n\n  * Persons with a history of cancer who are disease-free without treatment for three years or more are eligible.\n  * Persons with a history of histologically-confirmed basal cell carcinoma of the skin successfully treated with local excision only are excepted and are eligible, but other histologic types of skin cancer are exclusionary.\n  * Women who are disease-free three years or more after treatment for breast cancer and receiving long-term prophylaxis are eligible.\n* Diagnosed with excessive daytime sleepiness (unintended sleep episodes during the day present almost daily for at least one month), or narcolepsy; or history of narcolepsy in subject's parent, sibling or child.\n* Presence of a temperature ≥ 38.0ºC (≥100.4ºF), or acute symptoms greater than \"mild\" severity on the scheduled date of first vaccination.\n* Any confirmed or suspected immunosuppressive or immunodeficient condition including history of human immunodeficiency virus (HIV) infection.\n* Receipt of systemic glucocorticoids within 30 days prior to the first dose of study vaccine/placebo, or any other cytotoxic, immunosuppressive or immune-modifying drugs within 6 months of first study vaccine/placebo dose. Topical, intra-articularly injected, or inhaled glucocorticoids, topical calcineurin inhibitors or imiquimod are allowed.\n* Any significant disorder of coagulation or treatment with warfarin derivatives or heparin. Persons receiving individual doses of low molecular weight heparin outside of 24 hours prior to vaccination are eligible. Persons receiving prophylactic antiplatelet medications, e.g., low-dose aspirin, and without a clinically-apparent bleeding tendency, are eligible.\n* An acute evolving neurological disorder or Guillain Barré Syndrome within 42 days of receipt of prior seasonal or pandemic influenza vaccine.\n* Administration of an inactive vaccine within 14 days or of a live attenuated vaccine within 30 days before the first dose of study vaccine/placebo.\n* Planned administration of any vaccine other than the study vaccine/placebo before blood sampling at the Day 42 visit.\n* Previous administration of any H7 vaccine or physician-confirmed H7 disease.\n* Use of any investigational or non-registered product other than the study vaccine within 30 days preceding the first dose of study vaccine/placebo, or planned use during the study period.\n* Receipt of any immunoglobulins and/or any blood products within 90 days before the first dose of study vaccine/placebo, or planned administration of any of these products during the study period.\n* Any known or suspected allergy to any constituent of influenza vaccines or component used in the manufacturing process of the study vaccine including a history of anaphylactic-type reaction to consumption of eggs; or a history of severe adverse reaction to a previous influenza vaccine.\n* Any condition which, in the opinion of the investigator, prevents the subject from participating in the study.","healthyVolunteers":true,"sex":"ALL","minimumAge":"65 Years","stdAges":["OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"GSK Clinical Trials","affiliation":"GlaxoSmithKline","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"GSK Investigational Site","city":"Hollywood","state":"Florida","zip":"33024","country":"United States","geoPoint":{"lat":26.0112,"lon":-80.14949}},{"facility":"GSK Investigational Site","city":"Meridian","state":"Idaho","zip":"83642","country":"United States","geoPoint":{"lat":43.61211,"lon":-116.39151}},{"facility":"GSK Investigational Site","city":"Lenexa","state":"Kansas","zip":"66219","country":"United States","geoPoint":{"lat":38.95362,"lon":-94.73357}},{"facility":"GSK Investigational Site","city":"Wichita","state":"Kansas","zip":"67207","country":"United States","geoPoint":{"lat":37.69224,"lon":-97.33754}},{"facility":"GSK Investigational Site","city":"Lexington","state":"Kentucky","zip":"40509","country":"United States","geoPoint":{"lat":37.98869,"lon":-84.47772}},{"facility":"GSK Investigational Site","city":"Truro","state":"Nova Scotia","zip":"B2N 1L2","country":"Canada","geoPoint":{"lat":45.36685,"lon":-63.26538}},{"facility":"GSK Investigational Site","city":"Greater Sudbury","state":"Ontario","zip":"P3E 1H5","country":"Canada","geoPoint":{"lat":46.49,"lon":-80.99001}},{"facility":"GSK Investigational Site","city":"Toronto","state":"Ontario","zip":"M9W 4L6","country":"Canada","geoPoint":{"lat":43.65333,"lon":-79.38389}}]},"referencesModule":{"references":[{"pmid":"28302407","type":"DERIVED","citation":"Madan A, Ferguson M, Rheault P, Seiden D, Toma A, Friel D, Soni J, Li P, Innis BL, Schuind A. Immunogenicity and safety of an AS03-adjuvanted H7N1 vaccine in adults 65years of age and older: A phase II, observer-blind, randomized, controlled trial. Vaccine. 2017 Apr 4;35(15):1865-1872. doi: 10.1016/j.vaccine.2017.02.057. Epub 2017 Mar 13."}]}},"resultsSection":{"participantFlowModule":{"preAssignmentDetails":"Out of 363 subjects enrolled in the study, 3 subjects did not receive any vaccination.","groups":[{"id":"FG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"FG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"FG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"FG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"FG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"periods":[{"title":"Overall Study","milestones":[{"type":"STARTED","achievements":[{"groupId":"FG000","numSubjects":"60"},{"groupId":"FG001","numSubjects":"60"},{"groupId":"FG002","numSubjects":"60"},{"groupId":"FG003","numSubjects":"60"},{"groupId":"FG004","numSubjects":"120"}]},{"type":"COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"58"},{"groupId":"FG002","numSubjects":"58"},{"groupId":"FG003","numSubjects":"59"},{"groupId":"FG004","numSubjects":"116"}]},{"type":"NOT COMPLETED","achievements":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"2"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"4"}]}],"dropWithdraws":[{"type":"Serious Adverse Event","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"2"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Withdrawal by Subject","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Protocol non-compliance","reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"0"},{"groupId":"FG004","numSubjects":"1"}]},{"type":"Lost to Follow-up","reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"1"},{"groupId":"FG002","numSubjects":"0"},{"groupId":"FG003","numSubjects":"1"},{"groupId":"FG004","numSubjects":"1"}]}]}]},"baselineCharacteristicsModule":{"groups":[{"id":"BG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"BG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"BG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"BG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"BG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"BG005","title":"Total","description":"Total of all reporting groups"}],"denoms":[{"units":"Participants","counts":[{"groupId":"BG000","value":"60"},{"groupId":"BG001","value":"60"},{"groupId":"BG002","value":"60"},{"groupId":"BG003","value":"60"},{"groupId":"BG004","value":"120"},{"groupId":"BG005","value":"360"}]}],"measures":[{"title":"Age, Continuous","paramType":"MEAN","dispersionType":"STANDARD_DEVIATION","unitOfMeasure":"Years","classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"72.9","spread":"6.0"},{"groupId":"BG001","value":"73.9","spread":"6.3"},{"groupId":"BG002","value":"73.6","spread":"6.5"},{"groupId":"BG003","value":"73.4","spread":"5.3"},{"groupId":"BG004","value":"73.0","spread":"5.2"},{"groupId":"BG005","value":"73.30","spread":"5.75"}]}]}]},{"title":"Sex: Female, Male","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"categories":[{"title":"Female","measurements":[{"groupId":"BG000","value":"35"},{"groupId":"BG001","value":"37"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"36"},{"groupId":"BG004","value":"76"},{"groupId":"BG005","value":"214"}]},{"title":"Male","measurements":[{"groupId":"BG000","value":"25"},{"groupId":"BG001","value":"23"},{"groupId":"BG002","value":"30"},{"groupId":"BG003","value":"24"},{"groupId":"BG004","value":"44"},{"groupId":"BG005","value":"146"}]}]}]},{"title":"Race/Ethnicity, Customized","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","classes":[{"title":"Geographic Ancestry","categories":[{"title":"African Heritage/African American","measurements":[{"groupId":"BG000","value":"4"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"3"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"14"}]},{"title":"Asian - East Asian Heritage","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"2"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"3"}]},{"title":"Asian - South East Asian Heritage","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"}]},{"title":"White - Arabic/North African Heritage","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"}]},{"title":"White - Caucasian/European Heritage","measurements":[{"groupId":"BG000","value":"56"},{"groupId":"BG001","value":"59"},{"groupId":"BG002","value":"52"},{"groupId":"BG003","value":"57"},{"groupId":"BG004","value":"116"},{"groupId":"BG005","value":"340"}]},{"title":"Other","measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"}]}]}]}]},"outcomeMeasuresModule":{"outcomeMeasures":[{"type":"PRIMARY","title":"Number of Seroconverted (SCR) Subjects for Hemagglutination Inhibition (HI) Antibodies Against the Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain","description":"Seroconversion was defined as: For initially seronegative subjects \\[antibody titer below (\\<) 10 post-vaccination\\], antibody titer greater than or equal to (≥) 40 after vaccination; For initially seropositive subjects (antibody titer ≥ 10 prior to vaccination), antibody titer after vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was A/mallard/Netherlands/12/2000 NIBRG-63 (H7N1) (Flu A/mallard/NL/12/2000 H7N1).","populationDescription":"The analysis was performed on the According-to-Protocol (ATP) cohort for immunogenicity at Day 42, which included all evaluable subjects for whom data concerning immunogenicity outcome measure were available. This primary outcome measure was centered on the groups that received GSK2789869A vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Day 42","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of thee non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"112"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects Who Were Seroprotected for HI Antibodies Against the Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain","description":"A seroprotected subject was defined as a vaccinated subject with a serum HI titer greater than or equal to (≥) 1:40, that usually is accepted as indicating protection.","populationDescription":"The analysis was performed on the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects for whom data concerning immunogenicity outcome measure were available. This primary outcome measure was centered on the groups that received GSK2789869A vaccine.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Day 42","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"112"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"47"},{"groupId":"OG004","value":"1"}]}]}]},{"type":"PRIMARY","title":"Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain","description":"GMFR, also known as seroconversion factor (SCR) or mean geometric increase (MGI), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination (Day 0) reciprocal HI titer for the vaccine virus.","populationDescription":"The analysis was performed on the ATP cohort for immunogenicity at Day 42, which included all evaluable subjects for whom data concerning immunogenicity outcome measure were available. This primary outcome was centered on the groups that received GSK2789869A vaccine.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold increase","timeFrame":"At Day 42","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"112"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"7.3","upperLimit":"16.5"},{"groupId":"OG001","value":"18.9","lowerLimit":"14.0","upperLimit":"25.4"},{"groupId":"OG002","value":"16.0","lowerLimit":"10.8","upperLimit":"23.7"},{"groupId":"OG003","value":"18.2","lowerLimit":"12.6","upperLimit":"26.3"},{"groupId":"OG004","value":"1.0","lowerLimit":"1.0","upperLimit":"1.1"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any and Grade 3 Solicited Local Symptoms","description":"Assessed solicited local symptoms were pain, redness and swelling. Any = occurrence of the symptom regardless of intensity grade. Grade 3 pain = significant pain at rest; prevented normal activities as assessed by inability to attend/do work or school. Grade 3 redness/swelling = redness/swelling spreading beyond 100 millimeters (mm) of injection site.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the 7-day (Days 0-6) post-vaccination period following each dose and across doses","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"title":"Any Pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"34"},{"groupId":"OG002","value":"16"},{"groupId":"OG003","value":"29"},{"groupId":"OG004","value":"7"}]}]},{"title":"Grade 3 Pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Redness, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"}]}]},{"title":"Grade 3 Redness, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Swelling, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}]}]},{"title":"Grade 3 Swelling, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"3"}]}]},{"title":"Grade 3 Pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Any Redness, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Grade 3 Redness, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Swelling, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Grade 3 Swelling, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Pain, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"38"},{"groupId":"OG001","value":"39"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"8"}]}]},{"title":"Grade 3 Pain, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}]},{"title":"Any Redness, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"}]}]},{"title":"Grade 3 Redness, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Swelling, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}]}]},{"title":"Grade 3 Swelling, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any, Grade 3 and Related Solicited General Symptoms","description":"Assessed solicited general symptoms were fatigue, gastrointestinal symptoms (symptoms included nausea, vomiting, diarrhoea and/or abdominal pain), headache, joint pain at other location, muscle aches, shivering, sweating and fever \\[defined as axillary temperature equal to or above (≥) 38 degrees Celsius (°C)\\]. Any = occurrence of the symptom regardless of intensity grade or relationship to vaccination. Grade 3 symptom = general symptom that prevented normal everyday activities as assessed by inability to attend/do work or school, or required intervention of a physician/healthcare provider. Grade 3 fever = temperature \\> 39.0 °C. Related = symptom assessed by the investigator as related to the vaccination.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the 7-day (Days 0-6) post-vaccination period following each dose and across doses","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"title":"Any Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"14"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"22"}]}]},{"title":"Grade 3 Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"Related Fatigue, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"13"}]}]},{"title":"Any Fever, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Grade 3 Fever, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Related Fever, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"12"}]}]},{"title":"Grade 3 Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Related Gastrointestinal, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"7"}]}]},{"title":"Any Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"19"}]}]},{"title":"Grade 3 Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Headache, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"10"}]}]},{"title":"Any Joint pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"14"}]}]},{"title":"Grade 3 Joint pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Joint pain, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"}]}]},{"title":"Any Muscle aches, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"17"}]}]},{"title":"Grade 3 Muscle aches, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Muscle aches, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"12"}]}]},{"title":"Any Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}]}]},{"title":"Grade 3 Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Shivering, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"}]}]},{"title":"Any Sweating, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}]},{"title":"Grade 3 Sweating, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"Related Sweating, Dose 1","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}]}]},{"title":"Any Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"12"}]}]},{"title":"Grade 3 Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Fatigue, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"6"}]}]},{"title":"Any Fever, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Grade 3 Fever, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Fever, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"}]}]},{"title":"Grade 3 Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]},{"title":"Related Gastrointestinal, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]},{"title":"Any Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"9"}]}]},{"title":"Grade 3 Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Related Headache, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"5"}]}]},{"title":"Any Joint pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"10"}]}]},{"title":"Grade 3 Joint pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Joint pain, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"6"}]}]},{"title":"Any Muscle aches, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"11"}]}]},{"title":"Grade 3 Muscle aches, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Muscle aches, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"8"}]}]},{"title":"Any Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}]},{"title":"Grade 3 Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Related Shivering, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"Any Sweating, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}]}]},{"title":"Grade 3 Sweating, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Related Sweating, Dose 2","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"58"},{"groupId":"OG003","value":"57"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}]},{"title":"Any Fatigue, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"28"}]}]},{"title":"Grade 3 Fatigue, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"}]}]},{"title":"Related Fatigue, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"17"}]}]},{"title":"Any Fever, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Grade 3 Fever, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Fever, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"Any Gastrointestinal, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"16"}]}]},{"title":"Grade 3 Gastrointestinal, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]},{"title":"Related Gastrointestinal, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"9"}]}]},{"title":"Any Headache, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"24"}]}]},{"title":"Grade 3 Headache, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Headache, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"13"}]}]},{"title":"Any Joint pain, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"17"}]}]},{"title":"Grade 3 Joint pain, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"Related Joint pain, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"12"}]}]},{"title":"Any Muscle aches, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14"},{"groupId":"OG001","value":"21"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"16"},{"groupId":"OG004","value":"20"}]}]},{"title":"Grade 3 Muscle aches, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"Related Muscle aches, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"16"}]}]},{"title":"Any Shivering, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}]},{"title":"Grade 3 Shivering, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Related Shivering, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"}]}]},{"title":"Any Sweating, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}]},{"title":"Grade 3 Sweating, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"Related Sweating, Across doses","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Day 0","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"title":"ALT- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"ALT- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}]}]},{"title":"AST- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"AST- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"BAS- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"BAS- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"CRE- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"}]}]},{"title":"CRE- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"9"}]}]},{"title":"EOS- Below","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"8"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"13"}]}]},{"title":"EOS- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"4"}]}]},{"title":"HEM- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}]}]},{"title":"HEM- Above","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"9"}]}]},{"title":"HgB- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}]}]},{"title":"HgB- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"LYM- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}]},{"title":"LYM- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}]},{"title":"MON- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"6"}]}]},{"title":"MON- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"NEU- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"NEU- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"PLA- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"}]}]},{"title":"PLA- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]},{"title":"RBC- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"RBC- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"WBC- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"}]}]},{"title":"WBC- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available at Day 7.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Day 7","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"59"},{"groupId":"OG004","value":"120"}]}],"classes":[{"title":"ALT- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"ALT- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]},{"title":"AST- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"AST- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"BAS- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"BAS- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"CRE- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"5"}]}]},{"title":"CRE- Above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"8"}]}]},{"title":"EOS- Below","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"10"}]}]},{"title":"EOS- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}]},{"title":"HEM- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]},{"title":"HEM- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"6"}]}]},{"title":"HgB- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}]},{"title":"HgB- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"LYM- Below","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]},{"title":"LYM- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]},{"title":"MON- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"6"}]}]},{"title":"MON- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"NEU- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"NEU- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"}]}]},{"title":"PLA- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}]}]},{"title":"PLA- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]},{"title":"RBC- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"1"}]}]},{"title":"RBC- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"WBC- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"WBC- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available at Day 21.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Day 21","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"119"}]}],"classes":[{"title":"ALT- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"ALT- Above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}]}]},{"title":"AST- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"AST- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"}]}]},{"title":"BAS- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"BAS- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"CRE- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"}]}]},{"title":"CRE- Above","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"9"}]}]},{"title":"EOS- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"8"}]}]},{"title":"EOS- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"}]}]},{"title":"HEM- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"5"},{"groupId":"OG004","value":"2"}]}]},{"title":"HEM- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"4"}]}]},{"title":"HgB- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"}]}]},{"title":"HgB- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"LYM- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]},{"title":"LYM- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"MON- Below","categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"10"}]}]},{"title":"MON- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"NEU- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"NEU- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"PLA- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"5"}]}]},{"title":"PLA- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]},{"title":"RBC- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]},{"title":"RBC- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"WBC- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"WBC- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available at Day 28.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Day 28","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"classes":[{"title":"ALT- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"ALT-Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"3"}]}]},{"title":"AST- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"AST- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"BAS- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"BAS- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"CRE- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"2"}]}]},{"title":"CRE- Above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"8"}]}]},{"title":"EOS- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"9"}]}]},{"title":"EOS- Above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"2"}]}]},{"title":"HEM- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"}]}]},{"title":"HEM- Above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"HgB- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"4"}]}]},{"title":"HgB- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"LYM- Below","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]},{"title":"LYM- Above","categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"MON- Below","categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}]},{"title":"MON- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"NEU- Below","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"NEU- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"PLA- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"4"}]}]},{"title":"PLA- Above","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}]}]},{"title":"RBC- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}]},{"title":"RBC- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"WBC- Below","categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"WBC- Above","categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"1"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Abnormal Haematological and Biochemical Laboratory Values","description":"Among analysed biochemical parameters were alanine aminotransferase \\[ALT\\], aspartate aminotransferase \\[AST\\], basophils \\[BAS\\], creatinine \\[CRE\\], eosinophils \\[EOS\\], hematocrit \\[HEM\\], hemoglobin \\[HgB\\], lymphocytes \\[LYM\\], monocytes \\[MON\\], neutrophils \\[NEU\\], platelets \\[PLA\\], red blood cells \\[RBC\\] and white blood cells \\[WBC\\].","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available at Day 42.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Day 42","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"classes":[{"title":"ALT- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"ALT- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"58"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"6"}]}]},{"title":"AST- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"AST- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"BAS- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"BAS- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"CRE- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"7"}]}]},{"title":"CRE- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"8"}]}]},{"title":"EOS- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"10"}]}]},{"title":"EOS- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}]},{"title":"HEM- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"3"}]}]},{"title":"HEM- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]},{"title":"HgB- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"3"}]}]},{"title":"HgB- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"LYM- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"4"}]}]},{"title":"LYM- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]},{"title":"MON- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"18"}]}]},{"title":"MON- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"NEU- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"NEU- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]},{"title":"PLA- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"5"}]}]},{"title":"PLA- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}]},{"title":"RBC- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}]}]},{"title":"RBC- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]},{"title":"WBC- Below","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"2"}]}]},{"title":"WBC- Above","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"59"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"118"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any Medically-attended Adverse Events (MAEs)","description":"MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 0 up to Day 42","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"16"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)","description":"Any pIMD was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 0 up to Day 42","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 0 up to Day 42","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"17"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"21"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"35"}]}]}]},{"type":"PRIMARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 0 up to Day 42","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With HI Antibody Concentrations Above the Cut-off Value for Vaccine-homologous (H7N1)","description":"Seropositivity cut-off values assessed were equal to or above (≥) 1:10 in the sera of subjects seronegative before vaccination. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 0, 21, 42 and Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"114"}]}],"classes":[{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"3"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"18"},{"groupId":"OG002","value":"25"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"4"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"47"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"50"},{"groupId":"OG003","value":"48"},{"groupId":"OG004","value":"7"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"37"},{"groupId":"OG002","value":"35"},{"groupId":"OG003","value":"38"},{"groupId":"OG004","value":"4"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"10"},{"groupId":"OG004","value":"1"}]}]}]},{"type":"SECONDARY","title":"Titers for Antibodies Against Flu A/Mallard/NL/12/2000 Strain of Influenza Disease Vaccine-homologous (H7N1)","description":"Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"At Days 0, 21, 42 and Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"114"}]}],"classes":[{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"5.0","upperLimit":"5.0"},{"groupId":"OG001","value":"5.6","lowerLimit":"5.0","upperLimit":"6.4"},{"groupId":"OG002","value":"5.4","lowerLimit":"4.9","upperLimit":"5.8"},{"groupId":"OG003","value":"5.1","lowerLimit":"4.9","upperLimit":"5.4"},{"groupId":"OG004","value":"5.2","lowerLimit":"5.0","upperLimit":"5.5"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.2","lowerLimit":"6.5","upperLimit":"10.2"},{"groupId":"OG001","value":"8.9","lowerLimit":"7.0","upperLimit":"11.3"},{"groupId":"OG002","value":"11.1","lowerLimit":"8.6","upperLimit":"14.5"},{"groupId":"OG003","value":"10.6","lowerLimit":"8.2","upperLimit":"13.5"},{"groupId":"OG004","value":"5.3","lowerLimit":"5.0","upperLimit":"5.6"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"55.0","lowerLimit":"36.7","upperLimit":"82.5"},{"groupId":"OG001","value":"104.8","lowerLimit":"80.3","upperLimit":"136.7"},{"groupId":"OG002","value":"85.5","lowerLimit":"58.0","upperLimit":"126.1"},{"groupId":"OG003","value":"97.0","lowerLimit":"67.5","upperLimit":"139.4"},{"groupId":"OG004","value":"5.4","lowerLimit":"5.1","upperLimit":"5.8"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10.7","lowerLimit":"8.4","upperLimit":"13.7"},{"groupId":"OG001","value":"16.1","lowerLimit":"12.6","upperLimit":"20.5"},{"groupId":"OG002","value":"17.1","lowerLimit":"12.9","upperLimit":"22.6"},{"groupId":"OG003","value":"17.5","lowerLimit":"13.7","upperLimit":"22.2"},{"groupId":"OG004","value":"5.2","lowerLimit":"5.0","upperLimit":"5.5"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.7","lowerLimit":"5.0","upperLimit":"6.4"},{"groupId":"OG001","value":"5.9","lowerLimit":"5.2","upperLimit":"6.8"},{"groupId":"OG002","value":"6.6","lowerLimit":"5.6","upperLimit":"7.9"},{"groupId":"OG003","value":"7.2","lowerLimit":"5.7","upperLimit":"8.9"},{"groupId":"OG004","value":"5.0","lowerLimit":"5.0","upperLimit":"5.1"}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected (SPR) Subjects Against HI Antibodies for Vaccine-homologous (H7N1)","description":"Seroprotection (SPR) was defined as the proportion of subjects with H7N1 reciprocal HI titers equal to or above (≥) 1:40 against the tested vaccine virus. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 0, 21 and 42 and at Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"114"}]}],"classes":[{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"0"},{"groupId":"OG004","value":"1"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"1"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"56"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"53"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"49"},{"groupId":"OG002","value":"43"},{"groupId":"OG003","value":"47"},{"groupId":"OG004","value":"1"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"57"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"51"},{"groupId":"OG004","value":"114"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted (SCR) Subjects for HI Antibodies for Vaccine-homologous (H7N1)","description":"SCR was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer \\< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 21 and 42 and at Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"113"}]}],"classes":[{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"4"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"8"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"39"},{"groupId":"OG001","value":"45"},{"groupId":"OG002","value":"42"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"113"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"15"},{"groupId":"OG002","value":"15"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/Mallard/NL/12/2000 Strain of Influenza Disease Vaccine-homologous (H7N1)","description":"GMFR, also known as seroconversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold increase","timeFrame":"At Days 21 and 42 and at Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"113"}]}],"classes":[{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.6","lowerLimit":"1.3","upperLimit":"2.0"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.3","upperLimit":"1.9"},{"groupId":"OG002","value":"2.1","lowerLimit":"1.6","upperLimit":"2.7"},{"groupId":"OG003","value":"2.1","lowerLimit":"1.6","upperLimit":"2.6"},{"groupId":"OG004","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"55"},{"groupId":"OG003","value":"52"},{"groupId":"OG004","value":"112"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"11.0","lowerLimit":"7.3","upperLimit":"16.5"},{"groupId":"OG001","value":"18.9","lowerLimit":"14.0","upperLimit":"25.4"},{"groupId":"OG002","value":"16.0","lowerLimit":"10.8","upperLimit":"23.7"},{"groupId":"OG003","value":"18.2","lowerLimit":"12.6","upperLimit":"26.3"},{"groupId":"OG004","value":"1.0","lowerLimit":"1.0","upperLimit":"1.1"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"56"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"54"},{"groupId":"OG003","value":"50"},{"groupId":"OG004","value":"113"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2.1","lowerLimit":"1.7","upperLimit":"2.7"},{"groupId":"OG001","value":"3.0","lowerLimit":"2.3","upperLimit":"3.8"},{"groupId":"OG002","value":"3.2","lowerLimit":"2.4","upperLimit":"4.2"},{"groupId":"OG003","value":"3.4","lowerLimit":"2.7","upperLimit":"4.4"},{"groupId":"OG004","value":"1.0","lowerLimit":"1.0","upperLimit":"1.1"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"51"},{"groupId":"OG001","value":"55"},{"groupId":"OG002","value":"51"},{"groupId":"OG003","value":"46"},{"groupId":"OG004","value":"106"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"1.0","upperLimit":"1.3"},{"groupId":"OG001","value":"1.1","lowerLimit":"0.9","upperLimit":"1.3"},{"groupId":"OG002","value":"1.3","lowerLimit":"1.1","upperLimit":"1.5"},{"groupId":"OG003","value":"1.4","lowerLimit":"1.1","upperLimit":"1.8"},{"groupId":"OG004","value":"1.0","lowerLimit":"0.9","upperLimit":"1.0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With HI Antibody Concentrations Above the Cut-off Value for Vaccine-heterologous (H7N9)","description":"Seropositivity cut-off values assessed were equal to or above (≥) 1:10 in the sera of subjects seronegative before vaccination. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 0, 21 and 42 and at Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"1"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"12"},{"groupId":"OG003","value":"9"},{"groupId":"OG004","value":"1"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"1"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"10"},{"groupId":"OG001","value":"19"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"14"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"11"},{"groupId":"OG002","value":"11"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"1"}]}]}]},{"type":"SECONDARY","title":"Titers for Antibodies Against Flu A/Shanghai/2/2013 Strain of Influenza Disease Vaccine-heterologous (H7N9)","description":"Titers are presented as geometric mean titers (GMTs). The reference seropositivity cut-off value was equal to or above (≥) 1:10. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"At Days 0, 21 and 42 and at Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.0","lowerLimit":"5.0","upperLimit":"5.0"},{"groupId":"OG001","value":"5.3","lowerLimit":"4.7","upperLimit":"6.1"},{"groupId":"OG002","value":"5.2","lowerLimit":"4.8","upperLimit":"5.8"},{"groupId":"OG003","value":"5.8","lowerLimit":"4.7","upperLimit":"7.1"},{"groupId":"OG004","value":"5.2","lowerLimit":"4.8","upperLimit":"5.8"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"7.6","lowerLimit":"5.4","upperLimit":"10.7"},{"groupId":"OG001","value":"12.5","lowerLimit":"8.2","upperLimit":"18.9"},{"groupId":"OG002","value":"10.0","lowerLimit":"7.1","upperLimit":"13.9"},{"groupId":"OG003","value":"10.9","lowerLimit":"6.8","upperLimit":"17.4"},{"groupId":"OG004","value":"5.2","lowerLimit":"4.8","upperLimit":"5.8"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"64.3","lowerLimit":"36.6","upperLimit":"113.2"},{"groupId":"OG001","value":"201.3","lowerLimit":"142.6","upperLimit":"284.1"},{"groupId":"OG002","value":"96.4","lowerLimit":"51.6","upperLimit":"179.9"},{"groupId":"OG003","value":"179.9","lowerLimit":"103.1","upperLimit":"314.0"},{"groupId":"OG004","value":"5.2","lowerLimit":"4.8","upperLimit":"5.8"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"8.6","lowerLimit":"6.4","upperLimit":"11.6"},{"groupId":"OG001","value":"14.1","lowerLimit":"10.4","upperLimit":"19.1"},{"groupId":"OG002","value":"14.7","lowerLimit":"10.3","upperLimit":"20.9"},{"groupId":"OG003","value":"12.6","lowerLimit":"8.9","upperLimit":"17.7"},{"groupId":"OG004","value":"5.0","lowerLimit":"5.0","upperLimit":"5.0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"5.6","lowerLimit":"4.8","upperLimit":"6.6"},{"groupId":"OG001","value":"8.4","lowerLimit":"6.3","upperLimit":"11.1"},{"groupId":"OG002","value":"9.0","lowerLimit":"6.5","upperLimit":"12.3"},{"groupId":"OG003","value":"7.0","lowerLimit":"4.7","upperLimit":"10.4"},{"groupId":"OG004","value":"5.4","lowerLimit":"4.6","upperLimit":"6.2"}]}]}]},{"type":"SECONDARY","title":"Number of Seroprotected (SPR) Subjects Against HI Antibodies for Vaccine-heterologous (H7N9)","description":"Seroprotection (SPR) was defined as the proportion of subjects with H7N9 reciprocal HI titers equal to or above (≥) 1:40 against the tested vaccine virus. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 0, 21 and 42 and at Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"4"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Seroconverted (SCR) Subjects for HI Antibodies for Vaccine-heterologous (H7N9)","description":"SCR was defined as the proportion of subjects who had either a pre-vaccination reciprocal HI titer \\< 10 and a post-vaccination reciprocal titer ≥ 40, or a pre-vaccination reciprocal HI titer ≥ 10 and at least a 4-fold increase in post-vaccination reciprocal titer against the vaccine virus. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 21 and 42 and at Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"8"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"4"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"26"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"2"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/Shanghai/2/2013 Strain of Influenza Disease Vaccine-heterologous (H7N9)","description":"GMFR, also known as seroconversion factor (SCF), was defined as the geometric mean of the within-subject ratios of the post-vaccination reciprocal HI titer to the pre-vaccination reciprocal HI titer for the vaccine virus. The flu strain assessed was Flu A/Shanghai/2/2013 (H7N9).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Months 6 and 12 data were obtained from the ATP cohorts for immunogenicity at Months 6 and 12 respectively.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Fold increase","timeFrame":"At Days 21 and 42 and at Months 6 and 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.5","lowerLimit":"1.1","upperLimit":"2.2"},{"groupId":"OG001","value":"2.3","lowerLimit":"1.6","upperLimit":"3.5"},{"groupId":"OG002","value":"1.9","lowerLimit":"1.4","upperLimit":"2.6"},{"groupId":"OG003","value":"1.7","lowerLimit":"1.1","upperLimit":"2.5"},{"groupId":"OG004","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.1","lowerLimit":"8.1","upperLimit":"24.6"},{"groupId":"OG001","value":"37.7","lowerLimit":"25.8","upperLimit":"54.9"},{"groupId":"OG002","value":"18.4","lowerLimit":"9.8","upperLimit":"34.4"},{"groupId":"OG003","value":"28.7","lowerLimit":"15.6","upperLimit":"52.7"},{"groupId":"OG004","value":"1.0","lowerLimit":"1.0","upperLimit":"1.0"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.8","lowerLimit":"1.3","upperLimit":"2.4"},{"groupId":"OG001","value":"2.6","lowerLimit":"1.9","upperLimit":"3.6"},{"groupId":"OG002","value":"2.8","lowerLimit":"2.0","upperLimit":"4.0"},{"groupId":"OG003","value":"2.0","lowerLimit":"1.3","upperLimit":"3.2"},{"groupId":"OG004","value":"1.0","lowerLimit":"0.9","upperLimit":"1.1"}]}]},{"title":"Flu A/Shanghai/2/2013 (H7N9), Month 12","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"24"},{"groupId":"OG001","value":"28"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"23"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"1.1","lowerLimit":"1.0","upperLimit":"1.3"},{"groupId":"OG001","value":"1.6","lowerLimit":"1.2","upperLimit":"2.1"},{"groupId":"OG002","value":"1.7","lowerLimit":"1.2","upperLimit":"2.3"},{"groupId":"OG003","value":"1.2","lowerLimit":"0.7","upperLimit":"1.9"},{"groupId":"OG004","value":"1.0","lowerLimit":"0.8","upperLimit":"1.2"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With HI Neutralizing Antibody Concentrations Above the Cut-off Value for Vaccine-homologous (H7N1)","description":"Seropositivity cut-off values assessed were equal to or above (≥) 1:28 in the sera of subjects seronegative before vaccination. The flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Month 6 data was obtained from the ATP cohort for immunogenicity at Month 6.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 0, 21 and 42 and Month 6","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"2"},{"groupId":"OG001","value":"7"},{"groupId":"OG002","value":"3"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"3"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"9"},{"groupId":"OG001","value":"13"},{"groupId":"OG002","value":"9"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"2"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"24"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"2"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"3"}]}]}]},{"type":"SECONDARY","title":"Titers for Serum Neutralizing Antibodies Against Flu A/Mallard/NL/12/2000 Strain of Influenza Disease Vaccine-homologous (H7N1)","description":"Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/mallard/NL/12/2000. The reference seropositivity cut-off value was ≥ 1:28.","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Month 6 data was obtained from the ATP cohort for immunogenicity at Month 6.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"At Days 0, 21 and 42 and at Month 6","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.7","lowerLimit":"13.7","upperLimit":"15.8"},{"groupId":"OG001","value":"16.8","lowerLimit":"14.8","upperLimit":"18.9"},{"groupId":"OG002","value":"15.0","lowerLimit":"13.9","upperLimit":"16.3"},{"groupId":"OG003","value":"14.8","lowerLimit":"13.7","upperLimit":"16.0"},{"groupId":"OG004","value":"15.0","lowerLimit":"13.9","upperLimit":"16.2"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"17.5","lowerLimit":"15.4","upperLimit":"19.9"},{"groupId":"OG001","value":"21.2","lowerLimit":"17.5","upperLimit":"25.6"},{"groupId":"OG002","value":"18.2","lowerLimit":"15.5","upperLimit":"21.5"},{"groupId":"OG003","value":"21.9","lowerLimit":"17.6","upperLimit":"27.2"},{"groupId":"OG004","value":"14.7","lowerLimit":"13.7","upperLimit":"15.7"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"46.2","lowerLimit":"34.2","upperLimit":"62.5"},{"groupId":"OG001","value":"71.4","lowerLimit":"56.8","upperLimit":"89.7"},{"groupId":"OG002","value":"51.3","lowerLimit":"38.1","upperLimit":"69.1"},{"groupId":"OG003","value":"74.7","lowerLimit":"54.2","upperLimit":"102.9"},{"groupId":"OG004","value":"14.7","lowerLimit":"13.7","upperLimit":"15.7"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"26.7","lowerLimit":"22.7","upperLimit":"31.5"},{"groupId":"OG001","value":"38.5","lowerLimit":"32.1","upperLimit":"46.3"},{"groupId":"OG002","value":"33.5","lowerLimit":"27.0","upperLimit":"41.7"},{"groupId":"OG003","value":"39.4","lowerLimit":"31.6","upperLimit":"49.3"},{"groupId":"OG004","value":"15.0","lowerLimit":"13.9","upperLimit":"16.3"}]}]}]},{"type":"SECONDARY","title":"Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the Flu A/Mallard/NL/12/2000 (H7N1) Virus Strain","description":"Vaccine response was defined as: For initially seronegative subjects antibody titer ≥ 1:56 at post-vaccination\\]; For initially seropositive subjects antibody titer at post-vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was Flu A/mallard/NL/12/2000 (H7N1).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 21 and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Month 6 data was obtained from the ATP cohort for immunogenicity at Month 6.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 21 and 42 and at Month 6","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"1"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"22"},{"groupId":"OG002","value":"17"},{"groupId":"OG003","value":"19"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/mallard/NL/12/2000 (H7N1), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"9"},{"groupId":"OG002","value":"10"},{"groupId":"OG003","value":"13"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With HI Neutralizing Antibody Concentrations Above the Cut-off Value for Vaccine-heterologous (H7N9)","description":"Seropositivity cut-off values assessed were equal to or above (≥) 1:28 in the sera of subjects seronegative before vaccination. The flu strain assessed was Flu A/Anhui/1/2013 (H7N9).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21 and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Month 6 data was obtained from the ATP cohort for immunogenicity at Month 6.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 0, 21 and 42 and at Month 6","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/Anhui/1/2013 (H7N9), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"2"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Anhui/1/2013 (H7N9), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"12"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Anhui/1/2013 (H7N9), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"25"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"23"},{"groupId":"OG003","value":"24"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Anhui/1/2013 (H7N9), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"16"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"20"},{"groupId":"OG004","value":"1"}]}]}]},{"type":"SECONDARY","title":"Titers for Antibodies Against Flu A/Anhui/1/2013 Strain of Influenza Disease Vaccine-homologous (H7N9)","description":"Titers are presented as geometric mean titers (GMTs). The flu strain assessed was Flu A/Anhui/1/2013. The reference seropositivity cut-off value was ≥ 1:28.","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 0, 21, and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Month 6 data was obtained from the ATP cohort for immunogenicity at Month 6.","reportingStatus":"POSTED","paramType":"GEOMETRIC_MEAN","dispersionType":"95% Confidence Interval","unitOfMeasure":"Titers","timeFrame":"At Days 0, 21 and 42 and at Month 6","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/Anhui/1/2013 (H7N9), Day 0","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"14.0","lowerLimit":"14.0","upperLimit":"14.0"},{"groupId":"OG001","value":"14.4","lowerLimit":"13.6","upperLimit":"15.1"},{"groupId":"OG002","value":"14.0","lowerLimit":"14.0","upperLimit":"14.0"},{"groupId":"OG003","value":"14.8","lowerLimit":"13.7","upperLimit":"16.0"},{"groupId":"OG004","value":"14.0","lowerLimit":"14.0","upperLimit":"14.0"}]}]},{"title":"Flu A/Anhui/1/2013 (H7N9), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"15.1","lowerLimit":"13.9","upperLimit":"16.4"},{"groupId":"OG001","value":"20.1","lowerLimit":"16.8","upperLimit":"24.0"},{"groupId":"OG002","value":"16.5","lowerLimit":"14.8","upperLimit":"18.6"},{"groupId":"OG003","value":"21.3","lowerLimit":"17.3","upperLimit":"26.1"},{"groupId":"OG004","value":"14.0","lowerLimit":"14.0","upperLimit":"14.0"}]}]},{"title":"Flu A/Anhui/1/2013 (H7N9), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"44.0","lowerLimit":"32.4","upperLimit":"59.7"},{"groupId":"OG001","value":"79.1","lowerLimit":"60.5","upperLimit":"103.3"},{"groupId":"OG002","value":"53.8","lowerLimit":"37.8","upperLimit":"76.6"},{"groupId":"OG003","value":"85.6","lowerLimit":"60.9","upperLimit":"120.5"},{"groupId":"OG004","value":"14.0","lowerLimit":"14.0","upperLimit":"14.0"}]}]},{"title":"Flu A/Anhui/1/2013 (H7N9), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"24.8","lowerLimit":"19.6","upperLimit":"31.4"},{"groupId":"OG001","value":"34.2","lowerLimit":"27.3","upperLimit":"42.8"},{"groupId":"OG002","value":"36.1","lowerLimit":"27.6","upperLimit":"47.3"},{"groupId":"OG003","value":"35.9","lowerLimit":"28.9","upperLimit":"44.7"},{"groupId":"OG004","value":"14.3","lowerLimit":"13.7","upperLimit":"15.1"}]}]}]},{"type":"SECONDARY","title":"Vaccine Response Rate (VRR) for Microneutralization (MN) Antibodies Against the Flu A/Anhui/1/2013 (H7N9) Virus Strain","description":"Vaccine response was defined as: For initially seronegative subjects antibody titer ≥ 1:56 at post-vaccination\\]; For initially seropositive subjects antibody titer at post-vaccination ≥ 4 fold the pre-vaccination antibody titer. The Flu strain assessed was Flu A/Anhui/1/2013 (H7N9).","populationDescription":"The analysis was performed on the adapted According-to-Protocol cohort for immunogenicity, which included all evaluable subjects for which Days 21 and 42 data were obtained from the ATP cohort for immunogenicity at Day 42; Month 6 data was obtained from the ATP cohort for immunogenicity at Month 6.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"At Days 21 and 42 and at Month 6","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"classes":[{"title":"Flu A/Anhui/1/2013 (H7N9), Day 21","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"2"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"3"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Anhui/1/2013 (H7N9), Day 42","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"25"},{"groupId":"OG004","value":"30"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"13"},{"groupId":"OG001","value":"23"},{"groupId":"OG002","value":"18"},{"groupId":"OG003","value":"18"},{"groupId":"OG004","value":"0"}]}]},{"title":"Flu A/Anhui/1/2013 (H7N9), Month 6","denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"28"},{"groupId":"OG001","value":"29"},{"groupId":"OG002","value":"28"},{"groupId":"OG003","value":"23"},{"groupId":"OG004","value":"29"}]}],"categories":[{"measurements":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"13"},{"groupId":"OG003","value":"11"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Medically-attended Adverse Events (MAEs)","description":"MAEs were defined as events for which the subject received medical attention defined as hospitalization, an emergency room visit, or a visit to or from medical personnel (medical doctor) for any reason. Any MAE(s) = Occurrence of any MAE(s) regardless of intensity grade or relation to vaccination. Analysis of intensity and relationship to vaccination of MAEs was not performed.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 42 up to Month 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"24"},{"groupId":"OG002","value":"26"},{"groupId":"OG003","value":"21"},{"groupId":"OG004","value":"43"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Potential Immune-mediated Diseases (pIMDs)","description":"An pIMD was defined as an AE including autoimmune diseases and other mediated inflammatory disorders and assessed by the investigator as specific to the treatment administration.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"From Day 42 up to Month 12","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"},{"groupId":"OG002","value":"0"},{"groupId":"OG003","value":"1"},{"groupId":"OG004","value":"0"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Any Unsolicited Adverse Events (AEs)","description":"An unsolicited AE covers any untoward medical occurrence in a clinical investigation subject temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product and reported in addition to those solicited during the clinical study and any solicited symptom with onset outside the specified period of follow-up for solicited symptoms. Any was defined as the occurrence of any unsolicited AE regardless of intensity grade or relation to vaccination.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the 21-day (From Day 0 to Day 20) post-vaccination period after each dose","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"18"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"22"},{"groupId":"OG003","value":"17"},{"groupId":"OG004","value":"38"}]}]}]},{"type":"SECONDARY","title":"Number of Subjects With Serious Adverse Events (SAEs)","description":"SAEs assessed include medical occurrences that result in death, are life-threatening, require hospitalization or prolongation of hospitalization or result in disability/incapacity.","populationDescription":"The analysis was performed on the Total Vaccinated cohort (TVc), which included all vaccinated subjects for whom safety data were available.","reportingStatus":"POSTED","paramType":"COUNT_OF_PARTICIPANTS","unitOfMeasure":"Participants","timeFrame":"During the entire study period (From Day 0 up to Month 12)","groups":[{"id":"OG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."},{"id":"OG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21."}],"denoms":[{"units":"Participants","counts":[{"groupId":"OG000","value":"60"},{"groupId":"OG001","value":"60"},{"groupId":"OG002","value":"60"},{"groupId":"OG003","value":"60"},{"groupId":"OG004","value":"120"}]}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"7"},{"groupId":"OG003","value":"7"},{"groupId":"OG004","value":"13"}]}]}]}]},"adverseEventsModule":{"frequencyThreshold":"5","timeFrame":"Solicited local and general symptoms: during the 7-day (Days 0-6) post-vaccination period; Unsolicited AEs: within the 21-day (Days 0-20) post-vaccination period after each dose; SAEs: during the entire study period (from Day 0 up to Month 12).","eventGroups":[{"id":"EG000","title":"GSK2789869A F1 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 1 (F1), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","deathsNumAffected":0,"deathsNumAtRisk":60,"seriousNumAffected":3,"seriousNumAtRisk":60,"otherNumAffected":46,"otherNumAtRisk":60},{"id":"EG001","title":"GSK2789869A F2 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 2 (F2), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","deathsNumAffected":1,"deathsNumAtRisk":60,"seriousNumAffected":10,"seriousNumAtRisk":60,"otherNumAffected":48,"otherNumAtRisk":60},{"id":"EG002","title":"GSK2789869A F3 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 3 (F3), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","deathsNumAffected":2,"deathsNumAtRisk":60,"seriousNumAffected":7,"seriousNumAtRisk":60,"otherNumAffected":30,"otherNumAtRisk":60},{"id":"EG003","title":"GSK2789869A F4 Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of GSK2789869A H7N1 vaccine Formulation 4 (F4), administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","deathsNumAffected":0,"deathsNumAtRisk":60,"seriousNumAffected":7,"seriousNumAtRisk":60,"otherNumAffected":44,"otherNumAtRisk":60},{"id":"EG004","title":"Placebo Group","description":"Healthy male and female adults, 65 years of age and older, who received two doses of Placebo, administered intramuscularly in the deltoid region of the non-dominant arm at Day 0 and of the dominant arm at Day 21.","deathsNumAffected":0,"deathsNumAtRisk":120,"seriousNumAffected":13,"seriousNumAtRisk":120,"otherNumAffected":47,"otherNumAtRisk":120}],"seriousEvents":[{"term":"Anaemia","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Leukocytosis","organSystem":"Blood and lymphatic system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Angina pectoris","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Angina unstable","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Arrhythmia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Atrial fibrillation","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":120}]},{"term":"Atrioventricular block complete","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Bradycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Cardiac failure congestive","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":120}]},{"term":"Coronary artery disease","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Coronary artery stenosis","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Supraventricular tachycardia","organSystem":"Cardiac disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Haemorrhoids","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Large intestine polyp","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Vomiting","organSystem":"Gastrointestinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Chest pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Gait disturbance","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Cholangitis","organSystem":"Hepatobiliary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Bronchitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Cellulitis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Escherichia bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Gastroenteritis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Klebsiella bacteraemia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Lobar pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Pneumonia","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Sepsis","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Urinary tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Concussion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Contusion","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Hip fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Post procedural complication","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Spinal compression fracture","organSystem":"Injury, poisoning and procedural complications","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Arthralgia","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Fracture nonunion","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Osteoarthritis","organSystem":"Musculoskeletal and connective tissue disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Colon cancer metastatic","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Lung neoplasm malignant","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Metastases to liver","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Pancreatic carcinoma","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Prostate cancer","organSystem":"Neoplasms benign, malignant and unspecified (incl cysts and polyps)","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Seizure","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Syncope","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Mental status changes","organSystem":"Psychiatric disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Acute kidney injury","organSystem":"Renal and urinary disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Chronic obstructive pulmonary disease","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Dyspnoea","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Pleural effusion","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Pneumothorax spontaneous","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Aortic aneurysm","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Deep vein thrombosis","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Hypertension","organSystem":"Vascular disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG003","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]}],"otherEvents":[{"term":"Upper respiratory tract infection","organSystem":"Infections and infestations","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG002","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG003","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG004","numEvents":7,"numAffected":6,"numAtRisk":120}]},{"term":"Oropharyngeal pain","organSystem":"Respiratory, thoracic and mediastinal disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG004","numEvents":2,"numAffected":2,"numAtRisk":120}]},{"term":"Injection site pruritus","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":60},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Dizziness","organSystem":"Nervous system disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":0,"numAffected":0,"numAtRisk":60},{"groupId":"EG001","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":54,"numAffected":38,"numAtRisk":60},{"groupId":"EG001","numEvents":58,"numAffected":39,"numAtRisk":60},{"groupId":"EG002","numEvents":33,"numAffected":25,"numAtRisk":60},{"groupId":"EG003","numEvents":54,"numAffected":38,"numAtRisk":60},{"groupId":"EG004","numEvents":11,"numAffected":9,"numAtRisk":120}]},{"term":"Redness","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":1,"numAffected":1,"numAtRisk":60},{"groupId":"EG001","numEvents":4,"numAffected":4,"numAtRisk":60},{"groupId":"EG002","numEvents":2,"numAffected":1,"numAtRisk":60},{"groupId":"EG003","numEvents":4,"numAffected":4,"numAtRisk":60},{"groupId":"EG004","numEvents":1,"numAffected":1,"numAtRisk":120}]},{"term":"Swelling","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":3,"numAffected":2,"numAtRisk":60},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":60},{"groupId":"EG003","numEvents":2,"numAffected":2,"numAtRisk":60},{"groupId":"EG004","numEvents":0,"numAffected":0,"numAtRisk":120}]},{"term":"Fatigue","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":14,"numAffected":11,"numAtRisk":60},{"groupId":"EG001","numEvents":25,"numAffected":19,"numAtRisk":60},{"groupId":"EG002","numEvents":17,"numAffected":13,"numAtRisk":60},{"groupId":"EG003","numEvents":15,"numAffected":11,"numAtRisk":60},{"groupId":"EG004","numEvents":35,"numAffected":28,"numAtRisk":120}]},{"term":"Gastrointestinal","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":12,"numAffected":11,"numAtRisk":60},{"groupId":"EG001","numEvents":13,"numAffected":11,"numAtRisk":60},{"groupId":"EG002","numEvents":11,"numAffected":8,"numAtRisk":60},{"groupId":"EG003","numEvents":9,"numAffected":9,"numAtRisk":60},{"groupId":"EG004","numEvents":18,"numAffected":16,"numAtRisk":120}]},{"term":"Headache","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":18,"numAffected":13,"numAtRisk":60},{"groupId":"EG001","numEvents":26,"numAffected":17,"numAtRisk":60},{"groupId":"EG002","numEvents":20,"numAffected":13,"numAtRisk":60},{"groupId":"EG003","numEvents":15,"numAffected":11,"numAtRisk":60},{"groupId":"EG004","numEvents":31,"numAffected":24,"numAtRisk":120}]},{"term":"Joint pain","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":13,"numAffected":12,"numAtRisk":60},{"groupId":"EG001","numEvents":15,"numAffected":13,"numAtRisk":60},{"groupId":"EG002","numEvents":10,"numAffected":8,"numAtRisk":60},{"groupId":"EG003","numEvents":13,"numAffected":9,"numAtRisk":60},{"groupId":"EG004","numEvents":25,"numAffected":17,"numAtRisk":120}]},{"term":"Muscle aches","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":20,"numAffected":14,"numAtRisk":60},{"groupId":"EG001","numEvents":25,"numAffected":21,"numAtRisk":60},{"groupId":"EG002","numEvents":13,"numAffected":10,"numAtRisk":60},{"groupId":"EG003","numEvents":22,"numAffected":16,"numAtRisk":60},{"groupId":"EG004","numEvents":30,"numAffected":21,"numAtRisk":120}]},{"term":"Shivering (Chills)","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":6,"numAffected":4,"numAtRisk":60},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":60},{"groupId":"EG002","numEvents":5,"numAffected":4,"numAtRisk":60},{"groupId":"EG003","numEvents":3,"numAffected":3,"numAtRisk":60},{"groupId":"EG004","numEvents":8,"numAffected":7,"numAtRisk":120}]},{"term":"Sweating","organSystem":"General disorders","sourceVocabulary":"MedDRA 18.0","assessmentType":"SYSTEMATIC_ASSESSMENT","stats":[{"groupId":"EG000","numEvents":3,"numAffected":2,"numAtRisk":60},{"groupId":"EG001","numEvents":6,"numAffected":5,"numAtRisk":60},{"groupId":"EG002","numEvents":7,"numAffected":5,"numAtRisk":60},{"groupId":"EG003","numEvents":5,"numAffected":3,"numAtRisk":60},{"groupId":"EG004","numEvents":8,"numAffected":7,"numAtRisk":120}]}]},"moreInfoModule":{"certainAgreement":{"piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true,"otherDetails":"GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial."},"pointOfContact":{"title":"GSK Response Center","organization":"GlaxoSmithKline","phone":"866-435-7343"}}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-11-09"},"conditionBrowseModule":{"meshes":[{"id":"D007251","term":"Influenza, Human"}],"ancestors":[{"id":"D012141","term":"Respiratory Tract Infections"},{"id":"D007239","term":"Infections"},{"id":"D009976","term":"Orthomyxoviridae Infections"},{"id":"D012327","term":"RNA Virus Infections"},{"id":"D014777","term":"Virus Diseases"},{"id":"D012140","term":"Respiratory Tract Diseases"}]}},"hasResults":true}